Dr John Logue, Consultant Clinical Oncologist
Dr John Logue
Consultant Clinical Oncologist
Dr John Logue MB MRCP FRCR
Consultant Clinical Oncologist
Dr John Logue
Consultant Clinical Oncologist MB MRCP FRCR
Areas of expertise
- Prostate cancer
- Urological oncology
- Brachytherapy
- Image guided radiotherapy (IGRT)
- Intensity modulated radiotherapy (IMRT)
About Dr John Logue
GMC number: 2554879
Year qualified: 1981
Place of primary qualification: University of Glasgow
Areas of expertise
- Clinical oncology
- Urological oncology
Professional memberships
Articles by Dr John Logue
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 chhip trial
Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial
Updated analysis of the phase iii, double- blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (crpc) patients with bone metastases (alsympca)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 chhip trial
Outcome and patient-reported toxicity in localised prostate cancer treated with dose-escalated hypofractionated intensity-modulated radiotherapy
Dose-escalated hypofractionated intensity-modulated radiotherapy in high-risk carcinoma of the prostate: outcome and late toxicity
Pd-0178: parameterised rectal dose and associations with latetoxicity in high-dose-rate prostate brachytherapy
Ep-1223: endorectal balloons in prostate cancer radiotherapy: effects on seminal vesicle positioning